Istvan Tomaschek, MD
Neurology · Amherst, NYNPI 1487188819
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $27,976 of the $41,058 with a category attached, or 68.1%. 28 manufacturers reported payments, led by AbbVie at 48.6% of the total. 2025 is the largest year on record at $33,787, more than ten times the $147 reported in 2021.
Across 547 payments — averaging $75.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$20K
- Axsome Therapeutics, Inc.$8K
- Pfizer$7K
- Teva Pharmaceuticals USA, Inc.$1K
- Lundbeck LLC$924
- Lilly USA, LLC$817
- plus $3K from 22 others
Across 4 payments — averaging $39,472 each. An ownership or investment interest held by the physician or an immediate family member.
- Neurology Practice Consortium GPO, LLC$158K
What the payments were for
- Consulting fees$1,5254%
- Speaking & faculty fees$27,97668%
- Travel & lodging$3381%
- Food & beverage$11,09627%
- Education$1220%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 151 | $19,967 |
| Axsome Therapeutics, Inc. | 16 | $7,729 |
| Pfizer | 43 | $6,985 |
| Teva Pharmaceuticals USA, Inc. | 56 | $1,186 |
| Lundbeck LLC | 37 | $924 |
| Lilly USA, LLC | 43 | $817 |
| Tonix Medicines, Inc. | 60 | $732 |
| Impel Pharmaceuticals Inc. | 29 | $463 |
| Amgen | 16 | $430 |
| UCB, Inc. | 16 | $362 |
| Currax Pharmaceuticals LLC | 27 | $336 |
| Scilex Pharmaceuticals Inc. | 13 | $192 |
| Eisai Inc. | 7 | $154 |
| Biohaven Pharmaceuticals, Inc. | 1 | $122 |
| Averitas Pharma Inc. | 5 | $98 |
| Novo Nordisk | 4 | $92 |
| Upsher-smith Laboratories LLC | 3 | $77 |
| Impel Pharmaceuticals LLC | 4 | $74 |
| Azurity Pharmaceuticals, Inc. | 3 | $62 |
| Merck | 3 | $58 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $35 |
| CSL Behring | 1 | $28 |
| Novocure Inc. | 2 | $27 |
| Sanofi | 1 | $25 |
| Corium, LLC | 1 | $25 |
| Amneal Pharmaceuticals LLC | 1 | $21 |
| Collegium Pharmaceutical, Inc. | 1 | $19 |
| IBSA Pharma Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$41,058 in reported general payments places this provider in the 85th percentile of 1,623 neurology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| QuliptaAtogepant | 123 | $141,031 |
| Nurtec OdtRimegepant Sulfate | 80 | $103,295 |
| UbrelvyUbrogepant | 57 | $68,379 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 61 | $43,600 |
| Emgality PenGalcanezumab-Gnlm | 57 | $38,725 |
| Aimovig AutoinjectorErenumab-Aooe | 35 | $25,862 |
| Emgality SyringeGalcanezumab-Gnlm | 18 | $12,195 |
| Gabapentin | 91 | $894 |
| Amitriptyline Hcl | 153 | $775 |
| Oxcarbazepine | 24 | $549 |
| Sumatriptan Succinate | 49 | $388 |
| Propranolol Hcl | 28 | $259 |
| Topiramate | 18 | $152 |
| Methylprednisolone | 24 | $149 |
| Rosuvastatin Calcium | 13 | $90 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieQulipta, Ubrelvy | $19,967 | $209,410180 claims |
| PfizerNurtec Odt | $6,985 | $103,29580 claims |
| Upsher-smith Laboratories LLCTopiramate | $77 | $15218 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,623 neurology providers in New York.
Other neurology in Amherst
- Nicolas SaikaliAmherst$1.5M
- Jennifer McVigeAmherst$982K
- Bennett MyersAmherst$432K
- Laszlo MechtlerAmherst$347K
- Wisam ElmalikAmherst$289K
- Idan SharonBrooklyn$2.1M
- Allan PerelStaten Island$1.7M
- David KreitzmanCommack$1.5M
- Charles ArgoffAlbany$1.2M
- Stephen KriegerNew York$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.